Literature DB >> 10233749

B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

J J Jakubik1, M Saifuddin, D M Takefman, G T Spear.   

Abstract

We investigated the interaction of HIV immune complexes (HIV IC) with mononuclear cells from lymph nodes and blood. While antibody alone did not affect binding of HIV IC to mononuclear cells, antibody plus complement increased binding by as much as 10-fold and complement alone also increased binding slightly. Most of the increased binding of HIV IC to mononuclear cells was blocked by heat-inactivation of complement and by OKB7 monoclonal antibody, indicating that virus binding was to CR2 on B cells. A similar pattern of antibody and complement dependence for binding of HIV IC was observed with two model systems; Raji and Arent B-cell lines. Most of the HIV IC that bound to lymph node cells were not internalized, but remained on the cell surface and were gradually released. However, even after 48 hr some HIV IC could be detected bound to cells. Under certain conditions, HIV IC were infectious for T cells if bound to B cells but not infectious if added directly to T cells. Additionally, HIV IC bound to B cells led to higher virus replication. These studies show that B lymphocytes from blood and lymph nodes can transfer infectious HIV IC to T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233749      PMCID: PMC2326775          DOI: 10.1046/j.1365-2567.1999.00304.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  38 in total

Review 1.  Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes.

Authors:  A Lanzavecchia
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

2.  Immune retention: immunological requirements for maintaining an easily degradable antigen in vivo.

Authors:  J G Tew; T E Mandel; G A Miller
Journal:  Aust J Exp Biol Med Sci       Date:  1979-08

3.  Antigenic phenotyping of human follicular dendritic cells isolated from nonmalignant and malignant lymphatic tissue.

Authors:  S Petrasch; C Perez-Alvarez; J Schmitz; M Kosco; G Brittinger
Journal:  Eur J Immunol       Date:  1990-05       Impact factor: 5.532

4.  Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.

Authors:  W J Morrow; M Wharton; R B Stricker; J A Levy
Journal:  Clin Immunol Immunopathol       Date:  1986-09

5.  Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.

Authors:  G T Spear; D M Takefman; S Sharpe; M Ghassemi; S Zolla-Pazner
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

6.  Immune complexes in the acquired immunodeficiency syndrome (AIDS): relationship to disease manifestation, risk group, and immunologic defect.

Authors:  J S McDougal; M Hubbard; J K Nicholson; B M Jones; R C Holman; J Roberts; D B Fishbein; H W Jaffe; J E Kaplan; T J Spira
Journal:  J Clin Immunol       Date:  1985-03       Impact factor: 8.317

7.  Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

8.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

9.  Activation of complement on the surface of cells infected by human immunodeficiency virus.

Authors:  G T Spear; A L Landay; B L Sullivan; B Dittel; T F Lint
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

10.  A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus.

Authors:  R A Ezekowitz; M Kuhlman; J E Groopman; R A Byrn
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  8 in total

1.  DC-SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions.

Authors:  S Pöhlmann; G J Leslie; T G Edwards; T Macfarlan; J D Reeves; K Hiebenthal-Millow; F Kirchhoff; F Baribaud; R W Doms
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  CD4-Negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells.

Authors:  G G Olinger; M Saifuddin; G T Spear
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2.

Authors:  L Kacani; W M Prodinger; G M Sprinzl; M G Schwendinger; M Spruth; H Stoiber; S Döpper; S Steinhuber; F Steindl; M P Dierich
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 4.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

5.  Simian immunodeficiency virus (SIV)/immunoglobulin G immune complexes in SIV-infected macaques block detection of CD16 but not cytolytic activity of natural killer cells.

Authors:  Qing Wei; Jackie W Stallworth; Patricia J Vance; James A Hoxie; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2006-07

6.  DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes.

Authors:  Giovanna Rappocciolo; Paolo Piazza; Craig L Fuller; Todd A Reinhart; Simon C Watkins; David T Rowe; Mariel Jais; Phalguni Gupta; Charles R Rinaldo
Journal:  PLoS Pathog       Date:  2006-07       Impact factor: 6.823

Review 7.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

Review 8.  HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells.

Authors:  Charles R Rinaldo
Journal:  Scientifica (Cairo)       Date:  2013-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.